NYSE:CTLT - Catalent Stock Price, Forecast & News

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent Inc (NYSE:CTLT) issued its quarterly earnings data on Tuesday, November, 5th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.19 by $0.07. The firm earned $664.70 million during the quarter, compared to the consensus estimate of $634.87 million. Catalent had a net margin of 5.77% and a return on equity of 15.30%. The business's revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period last year, the business posted $0.28 earnings per share. View Catalent's Earnings History.

Catalent is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Catalent.

Catalent will be holding an earnings conference call on Monday, February 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

6 brokerages have issued 1-year price objectives for Catalent's stock. Their forecasts range from $49.00 to $64.00. On average, they expect Catalent's stock price to reach $58.67 in the next year. This suggests that the stock has a possible downside of 4.7%. View Analyst Price Targets for Catalent.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.

News coverage about CTLT stock has been trending very positive recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Catalent earned a daily sentiment score of 3.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Catalent.

Catalent saw a drop in short interest in December. As of December 31st, there was short interest totalling 4,610,000 shares, a drop of 6.5% from the December 15th total of 4,930,000 shares. Based on an average trading volume of 651,000 shares, the days-to-cover ratio is presently 7.1 days. Approximately 3.2% of the company's shares are short sold. View Catalent's Current Options Chain.

Some companies that are related to Catalent include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), GALAPAGOS NV/S (GLPG), Alnylam Pharmaceuticals (ALNY), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL) and Bausch Health Companies (BHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Alibaba Group (BABA), Energy Transfer LP Unit (ET), Thermo Fisher Scientific (TMO), AbbVie (ABBV), Verizon Communications (VZ), NVIDIA (NVDA), CVS Health (CVS), AT&T (T), Pfizer (PFE) and Home Depot (HD).

Catalent's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Ironvine Capital Partners LLC (0.19%), Norris Perne & French LLP MI (0.14%), Global Thematic Partners LLC (0.09%), Mountain Pacific Investment Advisers Inc. ID (0.08%), Three Peaks Capital Management LLC (0.04%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John J Greisch, John R Chiminski, Lance Miyamoto, Michael J Grippo, Peter L Buzy, Ricardo Pravda, Steven L Fasman and William Downie. View Institutional Ownership Trends for Catalent.

CTLT stock was sold by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC, State of Alaska Department of Revenue and We Are One Seven LLC. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, John R Chiminski, Lance Miyamoto, Michael J Grippo, Ricardo Pravda, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.

CTLT stock was purchased by a variety of institutional investors in the last quarter, including Three Peaks Capital Management LLC, Global Thematic Partners LLC, Nisa Investment Advisors LLC, McGuire Investment Group LLC, AdvisorShares Investments LLC, Mountain Pacific Investment Advisers Inc. ID, Ironvine Capital Partners LLC and Diversified Trust Co. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, John J Greisch and Peter L Buzy. View Insider Buying and Selling for Catalent.

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CTLT stock can currently be purchased for approximately $61.57.

Catalent has a market capitalization of $9.01 billion and generates $2.52 billion in revenue each year. The company earns $137.40 million in net income (profit) each year or $1.62 on an earnings per share basis. Catalent employs 12,300 workers across the globe.View Additional Information About Catalent.

The official website for Catalent is http://www.catalent.com/.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]